Clinical Trials
14
Active:10
Completed:4
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (33.3%)Phase 2
2 (33.3%)Phase 3
2 (33.3%)Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Orfagen
- Target Recruit Count
- 237
- Registration Number
- NCT01084148
Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis
Phase 3
Completed
- Conditions
- Uremic Xerosis
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- Orfagen
- Target Recruit Count
- 100
- Registration Number
- NCT01084720
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Phase 2
Completed
- Conditions
- Idiopathic Solar Urticaria
- Interventions
- Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]Drug: V0096 CR vehicle (formula RV3131A-MV1197)
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Orfagen
- Target Recruit Count
- 16
- Registration Number
- NCT00483496
- Locations
- 🇺🇸
Henry Ford Medical Center, Detroit, Michigan, United States
🇺🇸St Luke's Roosevelt Hospital Center, New York, New York, United States
🇬🇧Ninewells Hospital, Dundee, United Kingdom
Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.
Phase 2
Completed
- Conditions
- Congenital Venous Malformation
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Orfagen
- Target Recruit Count
- 32
- Registration Number
- NCT00462462
- Locations
- 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States
🇫🇷Hôpital Bretonneau Service de neuroradiologie, Tours Cedex 1, France
News
No news found